Snipd home pageGet the app
public
The HemOnc Pulse chevron_right

Graham Collins, MBBS, on New Agents, Prognostic Models in Hodgkin Lymphoma

Mar 9, 2023
35:20
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
1
Introduction
00:00 • 2min
chevron_right
2
Hodgkin Lymphoma at Ash - What's the Latest Big Trial?
02:02 • 4min
chevron_right
3
Is Bleamycin a Good Treatment for ABVD?
05:45 • 3min
chevron_right
4
ABVD Brintoxinab
08:32 • 2min
chevron_right
5
Is AAVD Brintoxinab for Neuropathy?
10:25 • 4min
chevron_right
6
Relapsed GVD - What's Next?
14:37 • 2min
chevron_right
7
Checkpoint Inhibitors in Hodgkin Lymphoma
16:53 • 2min
chevron_right
8
Nivo ICE - Phase Two Single Arm Study?
18:56 • 2min
chevron_right
9
Is NICE Better Than Ice?
20:48 • 2min
chevron_right
10
PD One Inhibitor
22:37 • 2min
chevron_right
11
Is CAR-T Cell a Relapsed Hodgkin Lymphoma?
24:42 • 2min
chevron_right
12
Early Stage Hodgkin Disease - Is There a Future?
26:37 • 3min
chevron_right
13
The Advanced Stage Hodgkin International Prognostic Index
29:23 • 3min
chevron_right
14
Is There a Way Forward With Hodgkin's Chemotherapy?
32:21 • 3min
chevron_right
In the latest episode of The HemOnc Pulse, Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil, a lymphoma specialist at Oxford Cancer and Haematology Centre, discusses the findings from the HoLISTIC Consortium, and what he thinks about checkpoint inhibitors upfront in the treatment of Hodgkin lymphoma.
HomeTop podcastsPopular guests